Challenge
A top 20 biopharmaceutical company faced a challenge with an oncology brand that offered strong clinical benefits but had a narrow treatment initiation window due to step therapy requirements. Many healthcare providers (HCPs) became aware of the therapy too late—after patients were no longer eligible. With no clear test or trigger to signal patient qualification, the brand struggled to drive timely patient starts.